// App-Quantinova.ai

85 : A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Neal D. Shore

Principal Investigators

  • Begona Mellado

  • Satish Shah

  • Ralph J. Hauke

  • Dan Costin

  • Thomas Morris

  • Rana Anjum

  • Zsolt Szijgyarto

  • Remy B Verheijen

  • Marie Cullberg

Medical Centers

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

  • Gettysburg Cancer Center, Gettysburg, PA

  • Nebraska Cancer Specialists, Omaha, NE

  • Center for Cancer Care at White Plains Hospital, White Plains, NY

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Waltham, MA

  • Johnson & Johnson, South Holland, Netherlands

  • AstraZeneca, Gothenburg, Sweden

Locations

  • United States

  • Spain

  • United Kingdom

  • Netherlands

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT04087174

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved